

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 237/22, 237/24, C07D 307/46, A61K 7/06, 31/165	A1	(11) International Publication Number: WO 00/18725 (43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/US99/22213 (22) International Filing Date: 24 September 1999 (24.09.99) (30) Priority Data: 60/102,448 30 September 1998 (30.09.98) US (71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US). (72) Inventors: McIVER, John, McMillan; 999 Indian Springs Drive, Cincinnati, OH 45241 (US). DEGENHARDT, Charles, Raymond; 20555 Wellingwood Court, Cincinnati, OH 45240 (US). EICKHOFF, David, Joseph; 505 Garden Way, Edgewood, KY 41017 (US). (74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).		(81) Designated States: AU, BR, CA, CN, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: 2-SUBSTITUTED KETOAMIDES (57) Abstract The present disclosure describes novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

2-SUBSTITUTED KETOAMIDES

5

10

FIELD OF THE INVENTION

The present invention relates to novel compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and / or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and may be useful for controlling parasites and invoking immunosuppression.

20

CROSS REFERENCE

This application claims priority under Title 35, United States Code § 119(e) from Provisional Application Serial No. 60/102,448, filed September 30, 1998.

BACKGROUND OF THE INVENTION

25

Hair loss is a common problem which occurs, for example, through natural processes or is often chemically promoted through the use of certain therapeutic drugs designed to alleviate conditions such as cancer. Often such hair loss is accompanied by lack of hair regrowth which causes partial or full baldness. Such baldness is cosmetically unappealing, and is particularly distressing to the person experiencing the hair loss.

30

As is well-known in the art, hair growth occurs by a cycle of activity which involves alternating periods of growth and rest. This cycle is often divided into three main stages which are known as anagen, catagen, and telogen. Anagen is the growth phase of the cycle and may be characterized by penetration of the hair follicle deep into the dermis with rapid proliferation of cells which are differentiating to form hair. The next phase is catagen, which is a transitional stage marked by the cessation of cell division, and during which the hair follicle regresses through the dermis and hair growth is ceased. The next phase, telogen, is often characterized as

the resting stage during which the regressed follicle contains a germ with tightly packed dermal papilla cells. At telogen, the initiation of a new anagen phase is caused by rapid cell proliferation in the germ, expansion of the dermal papilla, and elaboration of basement membrane components. This cycle is repeated throughout hair growth. Wherein hair growth ceases, most of the hair follicles reside in telogen and anagen is not engaged, thus causing the onset of full or partial baldness.

There have been many attempts in the literature to invoke the regrowth of hair by, for example, the promotion or prolongation of anagen. Currently, there are two drugs approved by the United States Food and Drug Administration for the treatment of male pattern baldness: topical minoxidil (marketed as Rogaine® by Pharmacia & Upjohn), and oral finasteride (marketed as Propecia® by Merck & Co., Inc.).


There are conflicting reports, however, regarding the ability of minoxidil to grow hair. In fact, early clinical studies investigating decreased blood pressure *via* the use of minoxidil did not even mention hypertrichosis (hair growth) as a side effect. See Dormois et al., "Minoxidil in Severe Hypertension: Value When Conventional Drugs Have Failed", American Heart Journal, Vol. 90, pp. 360 - 368 (1975). Indeed, the manufacturers of minoxidil have reported only limited hair growth in a portion of patients using minoxidil. See, e.g., Physician's Desk Reference®, 49th Ed. (1995), p. 2580. Furthermore, serious side effects of minoxidil are possible, including vasodilation (which leads to retention of fluid around the heart and increased heart rate), difficulty in breathing, and weight gain. Physician's Desk Reference®, 49th Ed. (1995), p. 2581.

Furthermore, while early indicators show that Propecia® may be more effective than Rogaine®, patients using Propecia® are experiencing limited hair growth. See The New England Journal of Medicine, Vol. 338, No. 9, February 26, 1998. Furthermore, potential side effects of Propecia® are serious. Propecia® may cause impotence, decreased sexual drive, decreased volume of ejaculate, breast tenderness and enlargement, and hypersensitivity reactions, including lip swelling and skin rash. Furthermore, Propecia® is not indicated for women and children. In fact, women who are pregnant or potentially pregnant should not even handle crushed or broken tablets containing the drug. See Physician's Desk Reference®, 52th Ed. (1998), p. 1737 and The New England Journal of Medicine, Vol. 338, No. 9, February 26, 1998.

Interestingly, the immunosuppressive agents cyclosporin A and FK506 are known to invoke a prominent hypertrichotic side effect. See Iwabuchi et al., "Effects of Immunosuppressive Peptidyl-Prolyl cis-trans Isomerase (PPIase) Inhibitors, Cyclosporin A, FK506, Ascomycin, and Rapamycin, on Hair Growth Initiation in Mouse: Immunosuppression is not Required for New Hair Growth", Journal of Dermatological Science, Vol. 9, pp. 64 - 69

(1995); Yamamoto et al., "Hair Growth-Stimulating Effects of Cyclosporin A and FK506, Potent Immunosuppressants", Journal of Dermatological Science, Vol. 7 (suppl.), pp. S47 - S54 (1994); Yamamoto et al., "Stimulation of Hair Growth by Topical Application of FK506, a Potent Immunosuppressive Agent", Journal of Investigational Dermatology, Vol. 102, pp. 160 - 164
5 (1994); Jiang et al., "Induction of Anagen in Telogen Mouse Skin by Topical Application of FK506, a Potent Immunosuppressant", Journal of Investigational Dermatology, Vol. 104, pp. 523 - 525 (1995); McElwee et al., "Topical FK506: A Potent Immunotherapy for Alopecia Areata? Studies Using the Dundee Experimental Bald Rat Model", British Journal of Dermatology, Vol. 137, pp. 491 - 497 (1997); Maurer et al., "Hair Growth Modulation by Topical Immunophilin
10 Ligands", American Journal of Pathology, Vol. 150, No. 4, pp. 1433 - 1441 (1997); and Paus et al., "Hair Growth Control by Immunosuppression", Arch. Dermatol. Res., Vol. 288, pp. 408 - 410 (1996). However, use of these compounds as hair growth actives may not be desirable due to their striking potency as immunosuppressive agents.

FK506 is a complex, macrocyclic molecule having the following structure:



15 Stocks et al., "The Contribution to Binding of the Pyranoside Substituents in the Excised Binding Domain of FK-506", Bioorganic & Medicinal Chemistry Letters, Vol. 4, No. 12, pp. 1457 - 1460 (1994). Analogs closely resembling this complex macrocycle have been disclosed as having hair growth properties in the form of, for example, alopecia areata and / or male pattern baldness. See,
20 e.g., Kawai et al., U.S. Patent No. 5,541,193, assigned to Abbott Laboratories, issued July 30, 1996; Asakura et al., U.S. Patent No. 5,496,564, assigned to Fujisawa Pharmaceutical Co., issued March 5, 1996; Baumann et al., U.S. Patent No. 5,352,671 assigned to Sandoz Ltd., issued October 4, 1994; and Rupprecht et al., U.S. Patent No. 5,550,233, assigned to Merck & Co., Inc., issued August 27, 1996.

25 However, excitement related to the hypertrichotic activities of cyclosporin A and FK506 is somewhat quelled by the lack of reports of hypertrichosis by various smaller, non-macrocyclic


immunosuppressive and non-immunosuppressive compounds which are less complex in structure than FK506. See Steiner et al., WO 96/40140, assigned to Guilford Pharmaceuticals, Inc., published December 19, 1996; Hamilton et al., WO 96/40633, assigned to Guilford Pharmaceuticals, Inc., published December 19, 1996; Steiner et al., U.S. Patent No. 5,696,135, assigned to GPI NIL Holdings, Inc., issued December 9, 1997; Hamilton et al., U.S. Patent No. 5,614,547, assigned to Guilford Pharmaceuticals, Inc., issued March 25, 1997; Steiner et al., WO 97/16190, assigned to Guilford Pharmaceuticals, Inc., published May 9, 1997; Zelle et al., WO 96/36630, assigned to Vertex Pharmaceuticals, Inc., published November 21, 1996; Armistead et al., WO 97/36869, assigned to Vertex Pharmaceuticals, Inc., published October 9, 1997; Zelle et al., WO 96/15101, assigned to Vertex Pharmaceuticals, Inc., published May 23, 1996; Armistead et al., WO 92/19593, assigned to Vertex Pharmaceuticals, Inc., published November 12, 1992; Armistead et al., WO 94/07858, assigned to Vertex Pharmaceuticals, Inc., published April 14, 1994; Zelle et al., WO 95/26337, assigned to Vertex Pharmaceuticals, Inc., published October 5, 1995; Duffy et al., WO 92/21313, assigned to Vertex Pharmaceuticals, Inc., published December 10, 1992; Armistead et al., U.S. Patent No. 5,192,773, assigned to Vertex Pharmaceuticals, Inc., issued March 9, 1993; Armistead et al., U.S. Patent No. 5,330,993, assigned to Vertex Pharmaceuticals, Inc., issued July 19, 1994; Armistead et al., U.S. Patent No. 5,622,970, assigned to Vertex Pharmaceuticals, Inc., issued April 22, 1997; Armistead et al., U.S. Patent No. 5,654,332, assigned to Vertex Pharmaceuticals, Inc., issued August 5, 1997; Armistead et al., U.S. Patent No. 5,620,971, assigned to Vertex Pharmaceuticals, Inc., issued April 15, 1997; Zelle et al., U.S. Patent No. 5,543,423, assigned to Vertex Pharmaceuticals, Inc., issued August 6, 1996; Armistead et al., U.S. Patent No. 5,516,797, assigned to Vertex Pharmaceuticals, Inc., issued May 14, 1996; Armistead et al., U.S. Patent No. 5,665,774, assigned to Vertex Pharmaceuticals, Inc., issued September 9, 1997; Andres et al., "Conformationally Defined Analogs of Prolylamides. *trans*-Prolyl Peptidomimetics", Journal of Organic Chemistry, Vol. 58, pp. 6609 - 6613 (1993); and Armistead et al., "Design, Synthesis and Structure of Non-macrocyclic Inhibitors of FKBP12, the Major Binding Protein for the Immunosuppressant FK506", Acta Crystallographica, D51, pp. 522 - 528 (1995).

Surprisingly, the present inventors have discovered a novel class of compounds which arrest and / or reverse hair loss or promote hair growth but do not share the complex, macrocyclic structure of FK506. The present inventors have further discovered compounds among this novel class which invoke hair growth yet are surprisingly non-immunosuppressive or are nominally immunosuppressive. The minimized and / or absent immunosuppressive activity of these

hypertrichotic compounds are distinct advantages as compared to the immunosuppressive compounds cyclosporin A and FK506.

SUMMARY OF THE INVENTION

5 The present invention relates to compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and / or reversing hair loss and promoting hair growth. The present compounds and compositions may also be useful against a variety of disorders including, for example, multi-drug resistance, human immunodeficiency virus (HIV), cardiac injury, and neurological disorders, and are useful for controlling parasites
10 and invoking immunosuppression. The compounds of the present invention have the structure:



and pharmaceutically acceptable salts, hydrates, and biohydrolyzable amides, esters, and imides
15 thereof, wherein the substituents Z, W, X, Y, V, A, G, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, and R₁₀ are defined herein.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds and compositions which are particularly useful for treating hair loss in mammals, including arresting and / or reversing hair loss and promoting hair growth.

5 In addition to discovering that the present compounds are useful for treating hair loss, the present inventors have also surprisingly discovered that immunosuppression is not required for hair growth stimulation. The present inventors have further discovered compounds that are useful for treating hair loss but are surprisingly non-immunosuppressive. Preferred compounds of the present invention are therefore, as defined herein, non-immunosuppressive. The present
10 compounds are also useful for treating a variety of other conditions as described herein below.

Publications and patents are referred to throughout this disclosure. All references cited herein are hereby incorporated by reference.

All percentages, ratios, and proportions used herein are by weight unless otherwise specified.

15

Definition and Usage of Terms

The following is a list of definitions for terms used herein:

As used herein "salt" is a cationic salt formed at any acidic (*e.g.*, carboxyl) group, or an anionic salt formed at any basic (*e.g.*, amino) group. Many such salts are known in the art.
20 Preferred cationic salts include the alkali metal salts (such as, for example, sodium and potassium), alkaline earth metal salts (such as, for example, magnesium and calcium), and organic salts. Preferred anionic salts include the halides (such as, for example, chloride salts). Such acceptable salts must, when administered, be appropriate for mammalian use.

As used herein unless otherwise specified, "alkenyl" is an unsubstituted or substituted,
25 straight or branched hydrocarbon chain radical having from 2 to about 15 carbon atoms; preferably from 2 to about 10 carbon atoms; more preferably from 2 to about 8 carbon atoms, and most preferably from about 2 to about 6 carbon atoms. Alkenyls have at least one olefinic double bond. Non-limiting examples of alkenyls include vinyl, allyl, and butenyl.

As used herein unless otherwise specified, "alkoxy" is an oxygen radical having an alkyl,
30 alkenyl, or alkynyl, preferably an alkyl or alkenyl, and most preferably an alkyl substituent. Examples of alkoxy radicals include -O-alkyl and -O-alkenyl. An alkoxy radical may be substituted or unsubstituted.

As used herein unless otherwise specified, "aryloxy" is an oxygen radical having an aryl substituent. An aryloxy radical may be substituted or unsubstituted.

As used herein unless otherwise specified, "alkyl" is an unsubstituted or substituted, straight or branched saturated hydrocarbon chain radical having from 1 to about 15 carbon atoms; preferably from 1 to about 10 carbon atoms; more preferably from 1 to about 6 carbon atoms; and most preferably from 1 to about 4 carbon atoms. Preferred alkyls include, for example, methyl, ethyl, propyl, *iso*-propyl, and butyl.

As used herein, "alkylene" refers to an alkyl, alkenyl, or alkynyl which is a diradical. For example, "methylene" is -CH₂-. Alkylenes may be substituted or unsubstituted.

As used herein unless otherwise specified, "aryl" is an aromatic ring radical which is either carbocyclic or heterocyclic. Preferred aryl groups include, for example, phenyl, benzyl, tolyl, xylyl, cumenyl, naphthyl, biphenyl, thienyl, furyl, pyrrolyl, pyridinyl, pyrazinyl, thiazolyl, pyrimidinyl, quinolinyl, triazolyl, tetrazolyl, benzothiazolyl, benzofuryl, indolyl, indenyl, azulenyl, fluorenyl, anthracenyl, oxazolyl, isoxazolyl, isotriazolyl, imidazolyl, pyrazolyl, oxadiazolyl, indolizynyl, indolyl, isoindolyl, purinyl, quinolizynyl, quinolinyl, isoquinolinyl, cinnolinyl, and the like. Aryls may be substituted or unsubstituted.

As used herein unless otherwise specified, "arylalkenyl" is an alkenyl radical substituted with an aryl group or an aryl radical substituted with an alkenyl group. Arylalkenyls may be substituted or unsubstituted.

As used herein unless otherwise specified, "arylalkyl" is an alkyl radical substituted with an aryl group or an aryl radical substituted with an alkyl group. Preferred arylalkyl groups include benzyl, phenylethyl, and phenylpropyl. Arylalkyls may be substituted or unsubstituted.

As used herein, "biohydrolyzable amides" are amides of the compounds of the present invention which do not interfere with the activity of the compound, or that are readily converted *in vivo* by a mammalian subject to yield an active compound.

As used herein, "biohydrolyzable esters" are esters of the compounds of the present invention which do not interfere with the activity of the compound, or that are readily converted *in vivo* by a mammalian subject to yield an active compound.

As used herein, "biohydrolyzable imides" are imides of the compounds of the present invention which do not interfere with the activity of the compound, or that are readily converted *in vivo* by a mammalian subject to yield an active compound.

As used herein unless otherwise specified, "carbocyclic ring", "carbocycle", or the like is a hydrocarbon ring radical. Carbocyclic rings are monocyclic or are fused, bridged, or spiro polycyclic rings. Unless otherwise specified, monocyclic rings contain from 3 to about 9 atoms, preferably from about 4 to about 7 atoms, and most preferably 5 or 6 atoms. Polycyclic rings contain from about 7 to about 17 atoms, preferably from about 7 to about 14 atoms, and most preferably 9 or 10 atoms. Carbocyclic rings (carbocycles) may be substituted or unsubstituted.

As used herein unless otherwise specified, "cycloalkyl" is a saturated carbocyclic or heterocyclic ring radical. Preferred cycloalkyl groups include, for example, cyclobutyl, cyclopentyl, and cyclohexyl. Cycloalkyls may be substituted or unsubstituted.

As used herein unless otherwise specified, "halo", "halogen", "halide", or the like means
5 a chloro, bromo, fluoro, or iodo atom radical, preferably bromo, chloro, or fluoro, more preferably chloro or fluoro.

As used herein unless otherwise specified, "heteroalkenyl" is an alkenyl radical containing carbon atoms and one or more heteroatoms within the alkenyl chain (e.g., -CHOCH₂ rather than pendant from like, e.g., C(O)) wherein the heteroatoms are selected from oxygen,
10 sulfur, nitrogen, and phosphorous, more preferably, oxygen, sulfur, and nitrogen. Heteroalkenyls may be substituted or unsubstituted.

As used herein unless otherwise specified, "heteroalkyl" is an alkyl radical containing carbon atoms and one or more heteroatoms within the alkyl chain (e.g., -CH₂OCH₂ rather than pendant from like, e.g., C(O)) wherein the heteroatoms are selected from the group consisting of
15 oxygen, sulfur, nitrogen, and phosphorous, more preferably, oxygen, sulfur, and nitrogen. Heteroalkyls may be substituted or unsubstituted.

As used herein unless otherwise specified, "heteroaryl" is an aryl radical containing carbon atoms and one or more heteroatoms within the aryl ring (e.g., -CHOCH-) rather than pendant from like, e.g., C(O)) wherein the heteroatoms are selected from the group consisting of
20 oxygen, sulfur, nitrogen, and phosphorous, more preferably, oxygen, sulfur, and nitrogen. Heteroaryls may be substituted or unsubstituted.

As used herein unless otherwise specified, "heteroarylalkenyl" is an arylalkenyl radical wherein the aryl group is a heteroaryl and / or the alkenyl group is a heteroalkenyl. Heteroarylalkenyls may be substituted or unsubstituted.

As used herein unless otherwise specified, "heteroarylalkyl" is an arylalkyl radical wherein the aryl group is a heteroaryl and / or the alkyl group is a heteroalkyl. Heteroarylalkyls may be substituted or unsubstituted.
25

As used herein unless otherwise specified, "heterocyclic ring", "heterocycle", or the like is a ring radical comprised of carbon atoms and one or more heteroatoms in the ring wherein the
30 heteroatoms are selected from the group consisting of oxygen, sulfur, nitrogen, and phosphorous, more preferably, oxygen, sulfur, and nitrogen. Heterocycles are monocyclic or are fused, bridged, or spiro polycyclic rings. Unless otherwise specified, monocycles contain from 3 to about 9 atoms, preferably from about 4 to about 7 atoms, and most preferably 5 or 6 atoms. Polycycles contain from about 7 to about 17 atoms, preferably from about 7 to about 14 atoms,

and most preferably 9 or 10 atoms. Heterocyclic rings (heterocycles) may be substituted or unsubstituted.

As used herein unless otherwise specified, "heterocycloalkyl" is a saturated heterocycle. Heterocycloalkyls may be substituted or unsubstituted.

5 As used herein unless otherwise specified, a "lower" moiety (e.g., "lower" alkyl) is moiety having 1 to about 6, preferably 1 to about 4, carbon atoms.

As used herein, "pharmaceutically acceptable" means suitable for use in a human or other mammal.

10 As used herein, "safe and effective amount of a compound" (or composition, or the like) means an amount that is effective to exhibit biological activity, preferably wherein the biological activity is arresting and / or reversing hair loss or promoting hair growth, at the site(s) of activity in a mammalian subject, without undue adverse side effects (such as toxicity, irritation, or allergic response), commensurate with a reasonable benefit / risk ratio when used in the manner of this invention.

15 As used herein, a "spiro moiety" is a cyclic moiety sharing a carbon on another ring, preferably the Z ring. Such spiro moiety may be carbocyclic or heterocyclic. Spiro moieties may be substituted or unsubstituted.


As used herein unless otherwise specified, the term "substituted" in reference to a group, moiety, or the like, means having one or more substituent groups each independently selected from hydrogen, alkoxy, hydroxy, nitro, amino, alkylamino, cyano, halo, carboxy, thiol, imino, and aryloxy (with additional allowed substituents on the G moiety which are selected from oxo, amido, -O-alkyl-C(O)OR₃₂, and -O-alkyl-C(O)NHR₃₂, wherein R₃₂ is selected from hydrogen and alkyl) preferably hydrogen, alkoxy, aryloxy, hydroxy, nitro, amino, halo, and thiol, more preferably hydrogen, alkoxy, hydroxy, nitro, amino, alkylamino, and halo, even more preferably 25 hydrogen, halo, hydroxy, and alkoxy, and most preferably hydrogen.

As used herein unless otherwise specified, the term "unsubstituted" means substitution by a hydrogen moiety. However, a group may alternatively be consistently described as being "substituted" wherein the substitution is with a hydrogen moiety.

30 As used herein, wherein any variable, moiety, group, or the like occurs more than one time in any variable or structure, its definition at each occurrence is independent of its definition at every other occurrence.

Compounds of the Present Invention

The compounds of the present invention have the structure:



- and pharmaceutically acceptable salts, hydrates, and biohydrolyzable amides, esters, and imides thereof, wherein:
- (a) Z is a saturated or unsaturated 4-, 5-, 6-, 7-, 8-, or 9-membered carbocycle or heterocycle wherein the heterocycle contains one or more heteroatoms selected from O, N, S, S(O), S(O₂), and P((O)OK);
 - (b) V is -CU-, wherein U is selected from hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl;
 - (c) G is selected from nil, O, S, and NR₁₇;
 - (d) K is selected from hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl;
 - (e) R₁ is selected from alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl;
 - (f) W is selected from nil, hydrogen, and lower alkyl;
 - (g) A is selected from nil and alkyl;
 - (h) X and Y are each, independently, selected from C(O), P(O), N, O, and S, wherein:
 - (i) when X is C(O) then R₃ is nil and Y is selected from N, O, and S;
 - (ii) when X is P(O) then R₃ is nil and Y is selected from N and O;
 - (iii) when X is N then R₃ is selected from hydrogen, alkyl, and arylalkyl, Y is selected from C(O) and P(O), and R₂ is nil;
 - (iv) when X is O then R₃ is nil, Y is selected from C(O) and P(O), and R₂ is nil;
 and
 - (v) when X is S then R₃ is nil, Y is C(O), and R₂ is nil;
 - (i) R₂ and R₃ are each, independently, selected from nil, hydrogen, alkyl, and arylalkyl;

- (j) R_4 is alkyl;
- (k) R_5 and R_6 are each, independently, selected from nil, hydrogen, alkyl having at least two carbon atoms, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl; or wherein R_5 and R_6 are bonded together to form a carbocyclic or heterocyclic ring;
- (l) R_7 , R_8 , R_9 , and R_{10} are each, independently, selected from nil, hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, halo, cyano, hydroxy, oxo, imino, $-R_{14}SR_{15}$, $-R_{14}S(O_2)R_{15}$, $-R_{14}S(O)R_{15}$, $-R_{14}C(O)R_{15}$, $-R_{14}C(O)NR_{15}R_{16}$, $-R_{14}C(O)OR_{15}$, $-R_{14}OR_{15}$, $-R_{14}NR_{15}R_{16}$, $-R_{14}P(O)NR_{15}R_{16}$, $-R_{14}P(O)OR_{15}R_{16}$, and a spiro moiety, and wherein R_7 and R_8 may be optionally bonded together to form an aromatic or saturated, carbocyclic or heterocyclic ring wherein the ring is fused to Z;
- (m) R_{14} and R_{15} are each, independently, selected from nil, hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl; and
- (n) R_{16} and R_{17} are each, independently, selected from hydrogen and alkyl.

The Ring System Z

The present compounds are comprised of a ring system, Z, which is a saturated or unsaturated 4-, 5-, 6-, 7-, 8-, or 9-membered carbocycle or heterocycle. Preferably the Z ring system is a 5-, 6-, or 7-membered carbocycle or heterocycle, more preferably a 5- or 6-membered carbocycle or heterocycle. Preferably, the Z ring is a carbocycle.

At the 1-position of the ring system is the V substituent which is -CU-, wherein U is selected from hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl, preferably hydrogen, alkyl, and arylalkyl, most preferably hydrogen.

The Z ring optionally contains one or more heteroatoms or heteromoieties (herein collectively described as heteroatoms for simplicity) wherein the heteroatoms are selected from oxygen (O), nitrogen (N), sulfur (S), sulfoxide (S(O)), sulfone (S(O)₂), and phosphonate (P((O)OK)). Preferably the optional heteroatoms are selected from the group consisting of O, N, S, S(O), and S(O)₂. Of course, the heteroatom cannot be at position 1 because the V substituent is required at position 1.

Wherein N is a heteroatom in the heterocycle, the additional N heteroatom must be substituted, most preferably with hydrogen or alkyl. The S(O), S(O)₂, and P(O)OK heteroatoms are depicted below in Table 1 for clarity:

20

Table 1

S(O)	S(O) ₂	P(O)OK

The G Moiety




Directly attached to the V substituent is the G moiety. G is selected from nil, O, S, and NR₁₇, wherein NR₁₇ is selected from hydrogen and alkyl. Preferably, G is selected from O, S, and NR₁₇, preferably O and NR₁₇, and most preferably, G is NR₁₇.

The R₁ Moiety

Directly attached to the G moiety is a ketoamide moiety as is shown in the above structure. The R₁ side chain is also directly attached to the ketoamide moiety. The R₁ moiety is selected from alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl. The R₁ moiety is preferably substituted with at least one substituent other than hydrogen. In addition to the substituents defined herein which can substitute on all moieties, the substituents oxo, amido, -O-alkyl-C(O)OR₃₂, and -O-alkyl-C(O)NHR₃₂, wherein R₃₂ is selected from hydrogen and alkyl, may also substitute on the R₁ moiety.

The R₁ moiety is preferably selected from alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, and heteroarylalkyl, even more preferably aryl, arylalkyl, and heteroarylalkyl, most preferably aryl. The most preferred aryl for the R₁ moiety is substituted aryl (most preferably substituted phenyl), particularly aryl having at least one alkoxy substituent. Particularly preferred R₁ moieties are shown below in Table 2.

Table 2 - Preferred R₁ Moieties

		
---	---	---

The Substituted A-X-Y-R₄ Moiety

At the 2-position of the Z ring is the A-X-Y-R₄ moiety which is substituted, as described herein, by R₂, R₃, R₅, and R₆.

The A moiety of the side chain is selected from nil and alkyl. Most preferably, the A moiety is nil. Of course, wherein A is nil, X is directly attached to the Z ring.

The X moiety of the side chain is dependent upon the structure of the Y moiety and *vice versa*. X and Y are each, independently, selected from C(O) (*i.e.*, carbonyl), P(O), N, O, S, with the following limitations:

- (i) when X is C(O) then R₃ is nil and Y is selected from the group consisting of N, O, and S;
- (ii) when X is P(O) then R₃ is nil and Y is selected from the group consisting of N and O;
- 5 (iii) when X is N then R₃ is selected from hydrogen, alkyl, and arylalkyl, Y is selected from the group consisting of C(O) and P(O), and R₂ is nil;
- (iv) when X is O then R₃ is nil, Y is selected from the group consisting of C(O) and P(O), and R₂ is nil; and
- (v) when X is S then R₃ is nil, Y is C(O), and R₂ is nil;

10 Preferably, X and Y are each, independently, selected from C(O), N, and O. More preferably, X and Y are each, independently, selected from C(O) and N.

X and Y are substituted by R₃ and R₂, respectively. R₃ and R₂ are each, independently, selected from nil, hydrogen, alkyl, and arylalkyl. Wherein X is N, then R₃ is selected from hydrogen, alkyl, and arylalkyl, preferably hydrogen and alkyl, most preferably hydrogen.

15 Wherein Y is N, then R₂ is selected from hydrogen, alkyl, and arylalkyl, more preferably hydrogen and alkyl, most preferably hydrogen.


The R₄ moiety is an alkyl moiety. The preferred alkyl moieties follow the preferred limitations set forth above, with the most preferred R₄ moiety being a methylene or methyne group (*i.e.*, a C₁ moiety bearing only one hydrogen substituent).

20 The R₅ and R₆ moieties are each directly attached to R₄. R₅ and R₆ are each, independently, selected from nil, hydrogen, alkyl having at least two carbon atoms, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl; or wherein R₅ and R₆ are bonded together to form a carbocyclic or heterocyclic ring; wherein at least one of R₅ and R₆ is not nil or hydrogen.

25 Preferably, R₅ and R₆ are each, independently, selected from nil, hydrogen, alkyl having at least two carbon atoms, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl. More preferably, R₅ and R₆ are each, independently, selected from alkyl having at least two carbon atoms, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, and heteroarylalkyl. Most preferably, R₅ and R₆ are each, independently, arylalkyl. It is often preferred that R₅ and R₆ are equivalent moieties. Of

30 course, R₅ and R₆ may be each, independently, substituted. Exemplary R₅ and R₆ moieties are shown in Table 3 below.

Table 3 - Exemplary R₅ and R₆ Moieties



The W Moiety

The Z ring may be substituted at the 2-position by an additional moiety, W. The W moiety is selected from nil, hydrogen, and lower alkyl, preferably hydrogen and lower alkyl, most preferably hydrogen. Wherein W is lower alkyl, W is most preferably methyl.

The Z Ring Substituents R₇, R₈, R₉, and R₁₀

In addition to the aforementioned substituents at positions 1 and 2 of the Z ring, the Z ring may also have additional substituents at the other available positions, such additional substituents being defined as R₇, R₈, R₉, and R₁₀. These substituents R₇, R₈, and R₉, and R₁₀ are each, independently, selected from nil, hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, halo, cyano, hydroxy, oxo, imino, -R₁₄SR₁₅, -R₁₄S(O₂)R₁₅, -R₁₄S(O)R₁₅, -R₁₄C(O)R₁₅, -R₁₄C(O)NR₁₅R₁₆, -R₁₄C(O)OR₁₅, -R₁₄OR₁₅, -R₁₄NR₁₅R₁₆, -R₁₄P(O)NR₁₅R₁₆, -R₁₄P(O)OR₁₅R₁₆, and a spiro moiety, and wherein R₇ and R₈ may be optionally bonded together to form an aromatic or saturated, carbocyclic or heterocyclic ring wherein the ring is fused to Z. R₁₄, and R₁₅ are each, independently, selected from nil, hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl. R₁₆ is selected from hydrogen and alkyl.

Preferably, R₇, R₈, and R₉, and R₁₀ are each, independently, selected from nil, hydrogen, alkyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, halo, hydroxy, oxo, -R₁₄SR₁₅, -R₁₄S(O₂)R₁₅, -R₁₄S(O)R₁₅, -R₁₄C(O)R₁₅, -R₁₄C(O)NR₁₅R₁₆, -R₁₄OR₁₅, -R₁₄NR₁₅R₁₆, and a spiro moiety, and wherein R₇ and R₈ may be optionally bonded together to form an aromatic or saturated, carbocyclic or heterocyclic second ring wherein the second ring is fused to Z. More preferably, R₇, R₈, and R₉, and R₁₀ are each, independently, selected from nil, hydrogen, alkyl, heteroalkyl, heteroalkenyl, aryl, arylalkyl, heteroarylalkyl, halo, hydroxy, oxo, -R₁₄SR₁₅, -R₁₄S(O₂)R₁₅, -R₁₄S(O)R₁₅, -R₁₄C(O)R₁₅, -R₁₄C(O)NR₁₅R₁₆, -R₁₄OR₁₅, -R₁₄NR₁₅R₁₆, and a spiro moiety, and wherein R₇ and R₈ may be optionally bonded

together to form an aromatic or saturated, carbocyclic or heterocyclic second ring wherein the second ring is fused to Z. Even more preferably, R_7 , R_8 , and R_9 , and R_{10} are each, independently, selected from nil, hydrogen, alkyl, heteroalkyl, heteroalkenyl, aryl, arylalkyl, heteroarylalkyl, halo, hydroxy, $-R_{14}C(O)R_{15}$, $-R_{14}C(O)NR_{15}R_{16}$, $-R_{14}OR_{15}$, $-R_{14}NR_{15}R_{16}$, and a spiro moiety, and


5 wherein R_7 and R_8 may be optionally bonded together to form an aromatic or saturated, carbocyclic or heterocyclic second ring wherein the second ring is fused to Z. Most preferably, R_7 and R_8 are bonded together to form an aromatic or saturated (preferably aromatic), carbocyclic or heterocyclic (preferably carbocyclic) second ring wherein the second ring is fused to Z.

Wherein R_7 and R_8 are bonded together to form an aromatic or saturated, carbocyclic or

10 heterocyclic second ring wherein the second ring is fused to Z, the second ring may, of course, be substituted or unsubstituted. A preferred second ring is phenyl.

Exemplary compounds of the present invention are presented in the following tables.

Table 4 - Exemplary Compounds of the Present Invention








Table 5 - Exemplary Compounds of the Present Invention




wherein, in Table 5, R_{18} , R_{19} , and R_{20} are each, independently, selected from hydrogen, alkoxy, aryloxy, hydroxy, nitro, amino, halo, and thiol.

Table 6 - Exemplary Compounds of the Present Invention



- 5 wherein in Table 6, R_{30} is selected from the group consisting of $-OR_{32}$ and $-OCH_2C(O)OR_{32}$, wherein R_{32} is selected from the group consisting of hydrogen and alkyl.


Table 7 - Exemplary Compounds of the Present Invention





wherein in Table 7, R_{35} is selected from hydrogen and $-OR_{36}$, wherein R_{36} is selected from hydrogen and alkyl.


5

Table 8 - Exemplary Compounds of the Present Invention









wherein in Table 8, R_{30} and R_{35} are each, independently, selected from $-OR_{32}$ and $-OCH_2C(O)OR_{32}$, wherein R_{32} is selected from hydrogen and alkyl.

Analytical Methods

5 The present compounds are hair growth actives, the more preferred among these being non-immunosuppressive. The compounds (test compounds) of the present invention may be tested for their ability to induce anagen and their immunosuppressive activity (or lack thereof) using the following methods. Alternatively, other methods well-known in the art may be used (but with the term "non-immunosuppressive" being defined according to the method disclosed
10 herein).

Telogen Conversion Assay:

15 The Telogen Conversion Assay measures the potential of a test compound to convert mice in the resting stage of the hair growth cycle ("telogen"), to the growth stage of the hair growth cycle ("anagen").

20 Without intending to be limited by theory, there are three principal phases of the hair growth cycle: anagen, catagen, and telogen. It is believed that there is a longer telogen period in C3H mice (Harlan Sprague Dawley, Inc., Indianapolis, IN) from approximately 40 days of age until about 75 days of age, when hair growth is synchronized. It is believed that after 75 days of age, hair growth is no longer synchronized. Wherein about 40 day-old mice with dark fur (brown or black) are used in hair growth experiments, melanogenesis occurs along with hair (fur) growth wherein the topical application of hair growth promoters are evaluated. The Telogen Conversion Assay herein below is used to screen compounds for potential hair growth by measuring melanogenesis.

25 Three groups of 44 day-old C3H mice are utilized: a vehicle control group, a positive control group, and a test compound group, wherein the test compound group is administered a compound of the present invention. The length of the assay is at least 19 days with 15 treatment

days (wherein the treatment days occur Mondays through Fridays). Day 1 is the first day of treatment. Most studies will end on Day 19, but a few may be carried out to Day 24 if the melanogenesis response looks positive, but occurs slowly. A typical study design is shown in Table 9 below:

5

Table 9

Group #	Animal #	Compound	Concentration	Application volume	Length of Study
1	1 - 10	Test Compound	5% in vehicle**	400 μ L topical	19 or 24 days
2	11 - 20	Cyclosporin A	0.19% in vehicle**	400 μ L topical	19 or 24 days
3	21 - 30	Vehicle**	N/A	400 μ L topical	19 or 24 days

**The vehicle is 60% ethanol, 20% propylene glycol, and 20% dimethyl isosorbide (commercially available from Sigma Chemical Co., St. Louis, MO).

The mice are treated topically Monday through Friday on their lower back (base of tail to the lower rib). A pipettor and tip are used to deliver 400 μ L to each mouse's back. The 400 μ L application is applied slowly while moving hair on the mouse to allow the application to reach the skin.

While each treatment is being applied to the mouse topically, a visual grade of from 0 to 4 will be given to the skin color in the application area of each animal. As the mice convert from telogen to anagen their skin color will become more bluish-black. As indicated in Table 10, the grades 0 to 4 represent the following visual observations as the skin progresses from white to bluish-black:

Table 10

<u>Visual Observation</u>	<u>Grade</u>
Whitish Skin Color	0
Skin is light gray (indication of initiation of anagen)	1
Appearance of Blue Spots	2
Blue Spots are aggregating to form one large blue area	3
Skin is dark blue (almost black) with color covering majority of treatment area (indication of mouse in full anagen)	4

Immunosuppression Assay:

The immunosuppression assay herein predicts the immunosuppressive activity of a compound of the present invention. The assay is performed as follows:

Spleens are excised from euthanized (CO₂ asphyxiation) adult male C3H mice ranging in
5 age from seven to sixteen weeks old (live mice commercially available from Harlan Sprague
Dawley, Inc., Indianapolis, IN). The spleens are placed immediately in cold Hanks Balanced Salt
Solution (HBSS, commercially available from Gibco-BRL, Gaithersburg, MD). The spleens are
then ground up between frosted glass slides and filtered through a sterile screen to remove tissue
debris. The resulting cell suspension is underlayered with an equal volume of Ficoll-Paque Plus
10 (commercially available from Pharmacia Biotech, Piscataway, NJ) and centrifuged at 400 x g for
approximately forty minutes at 20 °C in order to collect the splenocytes. The splenocytes are
collected from the interface using a disposable pipet and are washed twice with HBSS, followed
by centrifugation at 100 x g for ten min at 20 °C. Splenocytes are resuspended in five to ten mL
of cell culture media consisting of phenol red-free RPMI 1640 (culture media commercially
15 available from Gibco-BRL) containing 10% heat-inactivated fetal bovine serum (Gibco-BRL),
penicillin (50 U/mL), streptomycin (100 µg/mL), L-glutamine (2 mM), 2-mercaptoethanol (10⁻⁵
M), and N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (10 mM). The cells are
counted and checked for viability using, for example, trypan blue. Splenocytes are resuspended
in medium at 10⁶ cells/mL and pipetted into 96 well round bottom plates at 10⁵ cells/well.
20 Splenocytes are activated by addition of 50 µL/well of concanavalin A (final assay concentration
= 5 µg/ml) in the presence or absence of a test compound. Test compounds are made up as stock
solutions in methyl sulfoxide (DMSO), then diluted in medium and 50 µL/well added, such that
the final concentration of DMSO in the assay is below 0.05%. The plates are incubated at 37 °C
with 5% CO₂ for 48 hours. After 48 hours, the cells are pulsed with 1 µCi/well of methyl-³H-
25 thymidine (commercially available from Amersham, Buckinghamshire, England) and incubated
an additional 24 hours.

After 24 hours, the cells are harvested onto GF/C filter plates (commercially available
from Packard, Downers Grove, IL), solubilized in Microscint 20 (Packard), and counted on a
TopCount microplate scintillation and luminescence plate counter (Packard). Activity is
30 measured as a percentage of control activity in the absence of test compound and plotted *versus*
test compound concentration. The data are fit to a 4-parameter curve fit (Sigmaplot) and IC₅₀
values are calculated. As used herein, test compounds are considered non-immunosuppressive if,
by using this method, the ratio of (cyclosporin A IC₅₀/test compound IC₅₀) x 100 is less than or

equal to 0.02, *i.e.*, a non-immunosuppressive test compound has $\leq 2\%$ of the immunosuppressive activity of cyclosporin A.

Cell viability is assessed using the MTT (3-[4,5-dimethyl-thiazoyl-2-yl]2,5-diphenyl-tetrazolium bromide) dye assay as described by Nelson et al., Journal of Immunology, Vol. 150, No. 6, pp. 2139 - 2147 (1993), with the exception that the assay is carried out in serum-free, phenol red-free RPMI 1640 and the dye is solubilized in 100 μ L/well DMSO and read at an OD of 540 nm with a background correction at 650 nm on a SpectraMax Plus microplate reader (Molecular Devices, Menlo Park, CA).

10

Multi-Drug Resistance

As disclosed herein, the present compounds are also useful, for example, to increase the antiproliferative activity of a drug and / or prevent and / or treat multi-drug resistance. The present compounds may be assayed for this property as described in U.S. Patent No. 5,744,485, Zelle et al., assigned to Vertex Pharmaceuticals Inc., issued April 28, 1998, U.S. Patent No. 5,726,184, Zelle et al., assigned to Vertex Pharmaceuticals Inc., issued March 10, 1998, U.S. Patent No. 5,620,971, Armistead et al., assigned to Vertex Pharmaceuticals Inc., issued April 15, 1997, and U.S. Patent No. 5,543,423, Zelle et al., assigned to Vertex Pharmaceuticals Inc., issued August 6, 1996.

20

Methods of Making

The compounds of the present invention are prepared according to methods which are well-known to those skilled in the art. The starting materials used in preparing the compounds of the invention are known, made by known methods, or are commercially available as a starting material.

25

It is recognized that the skilled artisan in the art of organic chemistry can readily carry out standard manipulations of organic compounds without further direction. Examples of such manipulations are discussed in standard texts such as J. March, Advanced Organic Chemistry, John Wiley & Sons, 1992.

The skilled artisan will readily appreciate that certain reactions are best carried out when other functionalities are masked or protected in the compound, thus increasing the yield of the reaction and / or avoiding any undesirable side reactions. Often, the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many such manipulations can be found in, for example, T. Greene, Protecting Groups in Organic Synthesis, John Wiley & Sons, 1981.


The compounds of the present invention may have one or more chiral center. As a result, one may selectively prepare one optical isomer, including diastereomers and enantiomers, over another, for example by chiral starting materials, catalysts or solvents, or may prepare both stereoisomers or both optical isomers, including diastereomers and enantiomers at once (a racemic mixture). Since the compounds of the invention may exist as racemic mixtures, mixtures of optical isomers, including diastereomers and enantiomers, or stereoisomers may be separated using known methods, such as through the use of, for example, chiral salts and chiral chromatography.

In addition, it is recognized that one optical isomer, including a diastereomer and enantiomer, or a stereoisomer, may have favorable properties over the other. Thus, when disclosing and claiming the invention, when one racemic mixture is disclosed, it is clearly contemplated that both optical isomers, including diastereomers and enantiomers, or stereoisomers substantially free of the other are disclosed and claimed as well.

The following provides non-limiting examples illustrating more specifically the methods of making various compounds of the present invention.

As used herein, the following abbreviations are used:

<u>Reagent</u>	<u>Abbreviation</u>
N,N - dimethylformamide	DMF
1-hydroxybenzotriazole hydrate	HOBt
<i>tert</i> -butoxycarbonyl	BOC
(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (commercially available from Fluka Chemical, Switzerland)	PyBOP
tetrahydrofuran	THF
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride	EDAC
trimethylsilyl trifluoromethanesulfonate	TMS-OTf
N,N - diisopropylethylamine	i-Pr ₂ NEt or i-Pr ₂ EtN
trifluoroacetic acid	TFA
lithium hydroxide	LiOH
2-(<i>tert</i> -butoxycarbonyloxyimino)-2-phenylacetonitrile	Boc-ON
phenyl (moiety)	Ph or ph

Example 1

- 5 **1a.** 2-(1,7-Diphenyl-4-heptyl)-4,4-dimethyl-2-oxazoline: 2,4,4-Trimethyl-2-oxazoline (5.64 mL, 44.2 mmol) is dissolved in anhydrous THF (40 mL) at room temperature under inert atmosphere. The solution is cooled to -78 °C and *n*-butyllithium (31.3 mL / 1.6 M in hexanes, 50 mmol) is added dropwise. A solution of 1-bromo-3-phenylpropane (7.42 mL, 48.8 mmol) in THF (20 mL) is added dropwise over 10 minutes. The cooling bath is removed and the reaction solution is allowed to reach room temperature. After 30 minutes the solution is again cooled to -78 °C. *n*-Butyllithium (31.3 mL / 1.6 M in hexanes, 50 mmol) is added dropwise. After 30 minutes a solution of 1-bromo-3-phenylpropane (7.42 mL, 48.8 mmol) in THF (20 mL) is added dropwise over 10 minutes. The reaction is allowed to slowly reach room temperature over the next 12 hours with stirring. The reaction is poured onto water (200 mL) and acidified with 1N
- 10

HCl, and extracted with ethyl ether (150 mL). The aqueous layer is chilled, neutralized with 50% NaOH solution, and extracted with ethyl ether (3 x 100 mL). The combined ethyl ether extracts are dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification of the crude product by preparative chromatography over silica gel affords the desired *bis*-alkylated oxazoline **1a**.


5

1b. (1,7-Diphenyl-4-heptyl) carboxylic acid: Oxazoline **1a** (9.36 g, 26.8 mmol) is dissolved in dioxane (100 mL) at room temperature. 3N HCl (200 mL) is added and the resulting solution is heated at reflux for 18 hours. The solution is cooled to ambient temperature then poured onto water (200 mL) and extracted with ethyl ether (3 x 150 mL). The combined ethyl ether extracts
10 are washed successively with water (75 mL), and brine (75 mL) then dried over MgSO₄, filtered, and concentrated *in vacuo* to afford the desired product.

1c. *trans*-1,2-Diaminocyclohexane, (1,7-Diphenyl-4-heptyl) carboxylic acid amide: Carboxylic acid **1b** (1.0 g, 3.37 mmol) is dissolved in dichloromethane (50 mL) at room
15 temperature under inert atmosphere. *trans*-1,2-Diaminocyclohexane (0.77 g, 6.75 mmol) is added followed by *i*-Pr₂NEt (0.6 mL, 3.4 mmol) and PyBOP (1.9 g, 3.7 mmol). The reaction mixture is stirred at ambient temperature for 18 hours then poured onto ethyl acetate (300 mL) and washed successively with 0.1 N HCl (150 mL), saturated sodium bicarbonate solution (75 mL), and brine (50mL). The organic solution is dried over MgSO₄, filtered, and concentrated *in vacuo*.
20 Purification of the crude product by preparative chromatography over silica gel affords the desired product.

1d. *trans*-1,2-Diaminocyclohexane, 1-N-(1,7-Diphenyl-4-heptyl) carboxylic acid amide, 2-N-(3',4',5'-trimethoxyphenylglyoxyl) amide: Amide **1c** (0.73 g, 1.83 mmol) is dissolved in
25 anhydrous dichloromethane (30 mL) at room temperature. 3',4',5'-Trimethoxyphenylglyoxylic acid (0.67 g, 2.8 mmol) is added in one portion followed by triethylamine (0.6 mL, 4.3 mmol) and EDAC (0.53 g, 2.8 mmol). The reaction mixture is stirred for 18 hours at room temperature then poured onto water (50 mL) and extracted with dichloromethane (3 x 40 mL). The combined organic extracts are washed successively with 0.1 N HCl (40 mL), and saturated sodium
30 bicarbonate solution (40 mL) then dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification of the crude product by preparative chromatography over silica gel affords the desired product **1d**.

Example 2



2a. *cis*-2-(*N*-*tert*-Butoxycarbonylamino)-1-cyclopentanecarboxylic acid, 4-phenylbutylamide: *cis*-2-(*N*-*tert*-Butoxycarbonylamino)-1-cyclopentanecarboxylic acid (4.1 g, 17.7 mmol) is dissolved in 160 mL of DMF. 4-Phenylbutylamine (2.4 g, 16.1 mmol) and *i*-Pr₂NEt (5.6 mL, 32.2 mmol) are added followed by PyBOP (8.8 g, 16.9 mmol). The reaction is stirred for nineteen hours at room temperature, then poured onto ice-cold 0.1N HCl (600 mL) and extracted with ethyl acetate (600 mL). The organic layer is washed successively with brine (100 mL), saturated NaHCO₃ solution (300 mL), and brine (2 x 200 mL). The organic solution is dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification of the product by chromatography affords the desired amide **2a**.


2b. *cis*-2-amino-1-cyclopentanecarboxylic acid, 4-phenylbutylamide: The amide **2a** (5.5 g, 15.3 mmol) is dissolved in 150 mL of anhydrous dichloromethane. TFA (120 mL) is added dropwise over a 5 minute period. After 2 hours the mixture is cooled in an ice-bath and saturated K₂CO₃ solution is added until the pH is approximately 8. The mixture is transferred to a separatory funnel containing dichloromethane (200 mL) and water (200 mL) and shaken. The organic layer is washed with water (200 mL) before drying over MgSO₄. The mixture is filtered and concentrated *in vacuo* to afford the desired amine **2b**.

2c. *cis*-2-(3',4',5'-Trimethoxyphenylglyoxylamino)-1-cyclopentanecarboxylic acid, 4-phenylbutylamide: The amine **2b** (3.4 g, 13.1 mmol) is dissolved in 150 mL of anhydrous DMF. 3',4',5'-Trimethoxyphenylglyoxylic acid (3.9 g, 16.4 mmol) and *i*-Pr₂NEt (5.7 mL, 32.7 mmol) are added followed by PyBOP (8.85 g, 17.0 mmol). The reaction is stirred for 18 hours at room

temperature, then poured onto ice-cold 0.1N HCl (600 mL) and extracted with ethyl acetate (600 mL). The organic layer is washed successively with brine (100 mL), saturated NaHCO₃ solution (300 mL), and brine (2 x 100 mL). The organic solution is dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification of the product by chromatography affords the desired amide

5 **2c.**

Example 3



10

3a. *cis*-1,2-Diaminocyclohexane, (1,7-diphenyl-4-heptyl) carboxylic acid amide: Carboxylic acid **1b** (2.0 g, 6.74 mmol) is dissolved in DMF (100 mL) at room temperature under inert atmosphere. *cis*-1,2-Diaminocyclohexane (1.43 g, 12.5 mmol) is added followed by *i*-Pr₂NEt (1.18 mL, 6.8 mmol) and PyBOP (3.9 g, 7.45 mmol) in succession. The reaction mixture is stirred at ambient temperature for 18 hours then poured onto ethyl acetate (600 mL) and washed successively with 0.1 N HCl (300 mL), brine (100mL), saturated sodium bicarbonate solution (150 mL), and brine (100mL). The organic solution is dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification of the crude product by preparative chromatography over silica gel affords the desired amide **3a**.


20

3b. *cis*-1,2-Diaminocyclohexane, 1-N-(1,7-Diphenyl-4-heptyl) carboxylic acid amide, 2-N-(phenylglyoxyl) amide: The amine **3a** (1.46 g, 3.68 mmol) is dissolved in anhydrous DMF (50

mL) at room temperature. Phenylglyoxylic acid (0.8 g, 5.48 mmol) is added in one portion followed by *i*-Pr₂NEt (1.5 mL, 8.6 mmol) and PyBOP (2.9 g, 5.54 mmol). The reaction mixture is stirred for 18 hours at room temperature then poured onto ethyl acetate (300 mL) and washed successively with 0.1 N HCl (150 mL), brine (50 mL), saturated sodium bicarbonate solution (150 mL), and brine (50 mL). The organic solution is dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification of the crude product by preparative chromatography over silica gel affords the desired amide **3b**.

Example 4

10



4a. *cis*-2-(N-tert-Butoxycarbonylamino)-1-cyclohexanecarboxylic acid. *cis*-2-Amino-1-cyclohexanecarboxylic acid (5.0 g, 35 mmol) is dissolved in 40 mL of 1:1 dioxane:water. Triethylamine (7.3 mL, 52.4 mmol) is added followed by Boc-ON (9.5 g, 38.4 mmol). The mixture is stirred for 4 hours then poured onto water (75 mL) and extracted with ethyl acetate (3

times, 75 mL each). The aqueous solution is cooled in an ice-bath and the pH adjusted to approximately 2.5 with ice-cold 1N HCl solution. The resulting mixture is extracted with dichloromethane (3 times, 75 mL each). The combined organic extracts are dried over MgSO₄, filtered and concentrated *in vacuo* to afford **4a**.

5

4b. *cis*-2-(N-tert-Butoxycarbonylamino)-1-cyclohexanecarboxylic acid, 1,7-diphenyl-4-heptylamide: The carboxylic acid **4a** (4.3 g, 17.7 mmol) is dissolved in 160 mL of DMF. 1,7-Diphenyl-4-aminoheptane (4.3 g, 16.1 mmol) and *i*-Pr₂NEt (5.6 mL, 32.2 mmol) are added followed by PyBOP (8.8 g, 16.9 mmol). The reaction is stirred for 19 hours at room temperature, then poured onto ice-cold 0.1N HCl (600 mL) and extracted with ethyl acetate (600 mL). The layers are separated and the organic layer washed successively with brine (100 mL), saturated NaHCO₃ solution (300 mL) and brine (2 x 200 mL). The organic solution is dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification of the product by chromatography over silica gel affords the desired amide **4b**.

15




4c. *cis*-2-amino-1-cyclohexanecarboxylic acid, 1,7-diphenyl-4-heptylamide: The amide **4b** (7.54 g, 15.3 mmol) is dissolved in 150 mL of anhydrous dichloromethane. TFA (120 mL) is added dropwise over a 5 minute period. After 2 hours the mixture is cooled in an ice-bath and saturated K₂CO₃ solution is added until the pH is approximately 8. The mixture is transferred to a separatory funnel containing dichloromethane (200 mL) and water (200 mL) and shaken. The organic layer is separated and washed with water (200 mL) before drying over MgSO₄. The mixture is filtered and concentrated *in vacuo* to afford the desired amine **4c**.

20

4d. *cis*-2-(3',4',5'-Trimethoxyphenylglyoxylamino)-1-cyclohexanecarboxylic acid, 1,7-diphenyl-4-heptylamide: The amine **4c** (5.14 g, 13.1 mmol) is dissolved in 150 mL of anhydrous DMF. 3',4',5'-Trimethoxyphenylglyoxylic acid (3.93 g, 16.4 mmol) and *i*-Pr₂NEt (5.7 mL, 32.7 mmol) are added followed by PyBOP (8.9 g, 17.0 mmol). The reaction is stirred for 18 hours at room temperature, then poured onto ice-cold 0.1N HCl (600 mL) and extracted with ethyl acetate (600 mL). The layers are separated and the organic layer is washed successively with brine (100 mL), saturated NaHCO₃ solution (300 mL) and brine (2 x 100 mL). The organic solution is dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification of the product by chromatography over silica gel affords the desired amide **4d**.

30

Example 5



5a. *N*-(Diphenylmethylene)-2-amino-5-phenylpentanoic acid benzyl ester: *N*-(Diphenylmethylene)-glycine benzyl ester (20.0 g, 60.8 mmol) is dissolved in 130 mL of acetonitrile. 1-Bromo-3-phenylpropane (14.5 g, 72.8 mmol), K₂CO₃ (25.2 g, 182.2 mmol) and tetrabutylammonium bromide (1.96 g, 6.0 mmol) are added and the mixture is refluxed. After three hours the mixture is cooled to room temperature, filtered, and concentrated *in vacuo*. Water (400 mL) is added and the mixture is extracted with ether (1.2 L). The organic extract is washed with water (400 mL) and brine (200 mL), dried over MgSO₄, filtered, and concentrated *in vacuo*. The product is purified by chromatography over silica gel to afford the desired ester 5a.

5b. 2-Amino-5-phenylpentanoic acid benzyl ester: Ester 5a (24.62 g, 55.0 mmol) is dissolved in 1N aqueous HCl (600 mL) and ether (200 mL) and the mixture is stirred at room temperature. After 20 hours the layers are separated and the aqueous layer is extracted with ether (200 mL). The aqueous layer is cooled in an ice-bath and the pH adjusted to approximately 10 with saturated aqueous K₂CO₃ solution. The mixture is extracted with dichloromethane (3 x 300 mL)

and brine (100 mL) then dried over MgSO_4 , filtered, and concentrated *in vacuo* to afford the amino ester **5b**.


5c. *cis*-2-(*N*-*tert*-Butoxycarbonylamino)-1-cyclopentanecarboxylic acid, benzyl 5-phenyl-2-pentanoate amide: *cis*-2-(*N*-*tert*-Butoxycarbonylamino)-1-cyclopentanecarboxylic acid (4.8 g, 20.9 mmol) is dissolved in 230 mL of dichloromethane. Amino ester **5b** (5.4 g, 19.0 mmol) and *i*- Pr_2NEt (7.0 mL, 39.9 mmol) are added followed by PyBOP (10.9 g, 20.9 mmol). The reaction is stirred for 18 hours at room temperature, then poured onto ice-cold 0.1N HCl (250 mL) and extracted with ethyl acetate (300 mL). The layers are separated and the organic layer is washed with saturated NaHCO_3 solution (150 mL) and brine (50 mL). The organic solution is dried over MgSO_4 , filtered, and concentrated *in vacuo*. Purification of the product by chromatography on silica gel affords the desired amide **5c**.

5d. *cis*-2-amino-1-cyclopentanecarboxylic acid, benzyl 5-phenyl-2-pentanoate amide: The amide **5c** (9.6 g, 19.4 mmol) is dissolved in 185 mL of anhydrous dichloromethane. TFA (150 mL) is added dropwise over a 5 minute period. After two hours the mixture is cooled in an ice-bath and saturated K_2CO_3 solution is added until the pH is approximately 8. The mixture is transferred to a separatory funnel containing dichloromethane (250 mL) and water (250 mL) and shaken. The organic layer is separated and washed with water (200 mL). The water layer is back-extracted with dichloromethane (100 mL). The combined organic extracts are dried over MgSO_4 , filtered, and concentrated *in vacuo* to afford the desired amine **5d**.

5e. *cis*-2-(3',4',5'-Trimethoxyphenylglyoxylamino)-1-cyclopentanecarboxylic acid, benzyl 5-phenyl-2-pentanoate amide: The amine **5d** (7.14 g, 18.1 mmol) is dissolved in 220 mL of anhydrous dichloromethane. 3',4',5'-Trimethoxyphenylglyoxylic acid (5.2 g, 21.7 mmol) and *i*- Pr_2NEt (5.14 g, 39.8 mmol) are added followed by PyBOP (11.3 g, 21.7 mmol). The reaction is stirred for 13 hours at room temperature, then poured onto ice-cold 0.1N HCl (250 mL) and extracted with ethyl acetate (300 mL). The layers are separated and the organic layer washed with saturated NaHCO_3 solution (200 mL) and brine (50 mL). The organic solution is dried over MgSO_4 , filtered and concentrated *in vacuo*. Purification of the product by chromatography on silica gel affords the desired amide **5e**.

Example 6


36



6a. *N,N'*-Dimethyl-*trans*-1,2-Diaminocyclohexane, 5-phenylpentanoic acid amide: 5-Phenylpentanoic acid (6.0 g, 33.7 mmol) is dissolved in dichloromethane (500 mL) at room temperature under inert atmosphere. *N,N'*-Dimethyl-*trans*-1,2-diaminocyclohexane (9.6 g, 67.5 mmol) is added followed by *i*-Pr₂NEt (5.9 mL, 33.9 mmol) and PyBOP (19.3 g, 37.1 mmol). The reaction mixture is stirred at room temperature for 18 hours then poured onto ethyl acetate (300 mL) and washed successively with 0.1 N HCl (150 mL), saturated sodium bicarbonate solution (75 mL), and brine (50 mL). The organic solution is dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification of the crude product by preparative chromatography over silica gel affords the desired amide **6a**.


6b. *N,N'*-Dimethyl-*trans*-1,2-Diaminocyclohexane, 1-*N*-5-phenylpentanoic acid amide, 2-*N*-(phenylglyoxyl) amide: The amide **6a** (0.55 g, 1.83 mmol) is dissolved in anhydrous dichloromethane (30 mL) at room temperature. Phenylglyoxylic acid (0.42 g, 2.8 mmol) is added in one portion followed by *i*-Pr₂NEt (0.75 mL, 4.3 mmol) and PyBOP (1.44 g, 2.77 mmol) in succession. The reaction is stirred for 18 hours at room temperature, then poured onto ice-cold 0.1N HCl (30 mL) and extracted with dichloromethane (40 mL). The layers are separated and the organic layer is washed with saturated NaHCO₃ solution (30 mL) and brine (15 mL). Purification of the crude product by preparative chromatography over silica gel affords the desired product **6b**.

Example 7




7a. N,N'-Dimethyl-*trans*-1,2-Diaminocyclohexane, 1-N-5-phenylpentanoic acid amide, 2-N-(2-furyl)glyoxylic acid amide: N,N'-Dimethyl-*trans*-1,2-Diaminocyclohexane, 5-phenylpentanoic acid amide **6a** (10.0 g, 33.1 mmol) is dissolved in anhydrous dichloromethane (600 mL) at room temperature. Phenylglyoxylic acid (5.5 g, 49.7 mmol) is added in one portion followed by $i\text{-Pr}_2\text{NEt}$ (13.5 mL, 77.8 mmol) and PyBOP (25.8 g, 49.6 mmol) in succession. The reaction is stirred for 18 hours at room temperature, then poured onto ice-cold 0.1N HCl (600 mL) and extracted with dichloromethane (800 mL). The layers are separated and the organic layer washed with saturated NaHCO_3 solution (600 mL) and brine (300 mL). Purification of the crude product by preparative chromatography over silica gel affords the desired product **7a**.

Example 8



8b. *cis*-2-(2-butylglyoxylamino)-1-cyclohexanecarboxylic acid, 1,7-diphenyl-4-heptylamide: The amine **4c** (3.14 g, 8.0 mmol) is dissolved in 100 mL of anhydrous dichloromethane. 2-Butylglyoxylic acid (1.56 g, 12.0 mmol) and $i\text{-Pr}_2\text{NEt}$ (4.2 mL, 24.0 mmol) are added followed by PyBOP (7.3 g, 14.0 mmol). The reaction is stirred for 18 hours at room temperature, then poured onto ice-cold 0.1N HCl (100 mL) and extracted with ethyl acetate (150 mL). The layers are separated and the organic layer is washed successively with saturated NaHCO_3 solution (1500 mL) and brine (100 mL). The organic solution is dried over MgSO_4 , filtered, and concentrated *in vacuo*. Purification of the product by chromatography on silica gel affords the desired amide **8b**.

Example 9

- 5
- 9a.** Magnesium (40.2 g, 1.65 mol) and anhydrous ether (3.2 L) are combined in a reaction vessel with stirring. A solution of 1-bromo-3-phenyl propane in 1.6 L of anhydrous ether is added to an addition funnel. The bromide solution is added dropwise to the stirring reaction vessel over a 1 hour period. Upon completion of addition, the mixture stirs for 1 - 2 hours. A
- 10 solution of 4-phenylbutyronitrile (160 g, 1.1 mol) in anhydrous ether (2.4 L) is placed in the addition funnel. The solution is added to the reaction vessel over a 1 hour time period. Upon complete addition the solution is heated to reflux for 10 hours, and then stirs at room temperature for six hours to afford a solution of **9a**.
- 15 **9b.** 1,7-Diphenyl-4-aminoheptane: The reaction mixture of **9a** is diluted with methanol (3.2 L) using an addition funnel. Sodium borohydride (83.4 g, 2.2 mol) is added in portions. Upon complete addition the reaction is stirred at room temperature for six hours. The reaction mixture is quenched by a slow addition of water (3.2 L). The mixture is diluted with ether (3.2 L) and water (1.6 L). The ether layer is separated and the aqueous layer is extracted twice with ether
- 20 (3.2 L x 2). The combined ether extracts are washed once with sodium chloride solution, dried, filtered, and concentrated *in vacuo* to give the crude product. This product is diluted in ether (1.2 L) and acidified by slow addition of 1M HCl (1.2 L). The mixture stirs for one hour and is concentrated *in vacuo*. The resulting precipitate is diluted with acetonitrile and is stirred for 16 hours. The desired 1,7-Diphenyl-4-aminoheptane **9b** is collected by filtration.

25

Use of the Present Compounds

- The compounds herein may be used for the treatment of such conditions as, for example, treating hair loss in mammals, including arresting and / or reversing hair loss and promoting hair growth. Such conditions may manifest themselves in, for example, alopecia, including male
- 30 pattern baldness and female pattern baldness.

While certain of the present compounds may exhibit immunosuppressive activity, the preferred compounds of the present invention are, as defined herein, non-immunosuppressive.

Furthermore, in addition to treating hair loss, the compounds of the present invention may be used to treat a variety of clinical conditions which include, but are not limited to, multi-
5 drug resistance (particularly for use in cancer chemotherapy), neurological disorders and neurodegenerative diseases, cardiac injury associated with ischemia/reperfusion injury, and treatment of fungal, microbial, viral (especially HIV), malarial or other parasitic diseases or conditions. The present compounds may also be useful as inhibitors of multi-drug transporter proteins to enhance, for example, pharmacokinetics and bioavailability. Certain compounds of the
10 present invention may exhibit immunomodulatory properties. These compounds would prove useful in the treatment of organ transplant rejection and various autoimmune diseases which include, but are not limited to, Behcet's disease, Crohn's disease, systemic lupus erythematosus, psoriasis, rheumatoid arthritis, eczema, multiple sclerosis, myasthenia gravis, insulin-dependent diabetes mellitus, and Graves' disease. In addition, the present compounds may have utility for
15 the treatment of certain inflammatory and allergic disease states, including urticaria, allergic contact dermatitis, atopic dermatitis, atopic keratoconjunctivitis, inflammatory bowel disease, and asthma. The present compounds may also be useful in the treatment of cardiac hypertrophy in congestive heart failure.

The present compounds may also be useful in combination with a matrix
20 metalloproteinase inhibitor for treatment of various conditions including, for example, tissue destructive diseases mediated by excessive metalloproteinase activity, cancer, and multi-drug resistance, as well as all of the conditions previously mentioned herein above. Particularly preferred matrix metalloproteinase inhibitors useful in such combination include those described in U.S. Patent Application Serial No. 60/024,765, Pikul et al., assigned to The Procter & Gamble
25 Co., filed August 28, 1996, U.S. Patent Application Serial No. 60/024,842, Natchus et al., assigned to The Procter & Gamble Co., filed August 28, 1996, U.S. Patent Application Serial No. 60/024,846, Pikul et al., assigned to The Procter & Gamble Co., filed August 28, 1996, U.S. Patent Application Serial No. 60/024,746, Almstead et al., assigned to The Procter & Gamble Co., filed August 28, 1996, U.S. Patent Application Serial No. 60/024,830, Pikul et al., assigned
30 to The Procter & Gamble Co., filed August 28, 1996, U.S. Patent Application Serial No. 60/024,764, De et al., assigned to The Procter & Gamble Co., filed August 28, 1996, U.S. Patent Application Serial No. 60/024,764, De et al., assigned to The Procter & Gamble Co., filed August 28, 1996, and U.S. Patent Application Serial No. 60/024,766, Wang et al., assigned to The Procter & Gamble Co., filed August 28, 1996.

Preferably, the compounds of the present invention are formulated into pharmaceutical compositions for use in treatment or prophylaxis of conditions such as the foregoing. Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. (1990).

5 Typically, from about 5 mg to about 3000 mg, more preferably from about 5 mg to about 1000 mg, more preferably from about 10 mg to about 100 mg, of a compound of the present invention is administered per day for systemic administration. It is understood that these dosage ranges are by way of example only, and that daily administration can be adjusted depending on various factors. The specific dosage of the compound to be
10 administered, as well as the duration of treatment, and whether the treatment is topical or systemic are interdependent. The dosage and treatment regimen will also depend upon such factors as the specific compound used, the treatment indication, the efficacy of the compound, the personal attributes of the subject (such as, for example, weight, age, sex, and medical condition of the subject), compliance with the treatment regimen, and the presence
15 and severity of any side effects of the treatment.

In addition to the subject compound, the compositions of the subject invention contain a pharmaceutically-acceptable carrier ("carrier"). The term pharmaceutically-acceptable carrier, as used herein, means one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for administration to a mammal. The term "compatible", as used
20 herein, means that the components of the composition are capable of being commingled with a compound of the present invention, and with each other, in a manner such that there is no interaction which would substantially reduce the efficacy of the composition under ordinary use situations. Carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the animal, preferably mammal, being treated. The
25 carrier can itself be inert or it can possess pharmaceutical benefits of its own.

The compositions of this invention may be in any of a variety of forms, suitable (for example) for oral, rectal, topical, nasal, ocular or parenteral administration. Of these, topical or oral administration is especially preferred. Depending upon the particular route of administration desired, a variety of pharmaceutically-acceptable carriers well-known in
30 the art may be used. These include solid or liquid fillers, diluents, hydrotropes, surface-active agents, and encapsulating substances. Optional pharmaceutically-active materials may be included, which do not substantially interfere with the activity of the compound of the present invention. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the
35 compound. Techniques and compositions for making dosage forms useful in the methods of

this invention are described in the following references: Modern Pharmaceutics, Chapters 9 and 10, Banker & Rhodes, eds. (1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms, 2nd Ed., (1976).

Some examples of substances which can serve as pharmaceutically-acceptable carriers or components thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the TWEENS; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.

The choice of a pharmaceutically-acceptable carrier to be used in conjunction with the subject compound is basically determined by the way the compound is to be administered.

In particular, pharmaceutically-acceptable carriers for systemic administration include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffer solutions, emulsifiers, isotonic saline, and pyrogen-free water. Preferred carriers for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil. Preferably, the pharmaceutically-acceptable carrier, in compositions for parenteral administration, comprises at least about 90% by weight of the total composition.

Various oral dosage forms can be used, including such solid forms as tablets, capsules, granules and bulk powders. These oral forms comprise a safe and effective amount, usually at least about 5%, and preferably from about 25% to about 50%, of a compound of the present invention. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring agents and flavoring agents.

The pharmaceutically-acceptable carrier suitable for the preparation of unit dosage forms for oral administration are well-known in the art. Tablets typically comprise conventional

pharmaceutically-compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmellose; lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules (including time release and sustained release formulations) typically comprise one or more solid diluents disclosed above. The selection of carrier components depends on secondary considerations like taste, cost, and shelf stability, which are not critical for the purposes of the subject invention, and can be readily made by a person skilled in the art.

Orally administered compositions also include liquid solutions, emulsions, suspensions, powders, granules, elixirs, tinctures, syrups, and the like. The pharmaceutically-acceptable carriers suitable for preparation of such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. For a suspension, typical suspending agents include methyl cellulose, sodium carboxymethyl cellulose, AVICEL RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants disclosed above.

Such compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.

Other compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms. Such compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol; and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.

The compounds of the present invention may also be topically administered. The carrier of the topical composition preferably aids penetration of the present compounds into the skin to

reach the environment of the hair follicle. Topical compositions of the present invention may be in any form including, for example, solutions, creams, ointments, gels, lotions, shampoos, leave-on and rinse-out hair conditioners, milks, cleansers, moisturizers, sprays, skin patches, and the like.

5 Topical compositions containing the active compound can be admixed with a variety of carrier materials well known in the art, such as, for example, water, alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oil, propylene glycol, PPG-2 myristyl propionate, and the like.

10 Other materials suitable for use in topical carriers include, for example, emollients, solvents, humectants, thickeners and powders. Examples of each of these types of materials, which can be used singly or as mixtures of one or more materials, are as follows:

Emollients, such as stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, *iso*-propyl isostearate, stearic acid, *iso*-butyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, 15 octadecan-2-ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, di-*n*-butyl sebacate, *iso*-propyl myristate, *iso*-propyl palmitate, *iso*-propyl stearate, butyl stearate, polythylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, and myristyl myristate; propellants, such as 20 propane, butane, *iso*-butane, dimethyl ether, carbon dioxide, and nitrous oxide; solvents, such as ethyl alcohol, methylene chloride, *iso*-propanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran; humectants, such as glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, and gelatin; and powders, such as 25 chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, and ethylene glycol monostearate.

30 The compounds of the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. A preferred formulation for topical delivery of the present compounds utilizes liposomes such as described in Dowton et al., "Influence of 35 Liposomal Composition on Topical Delivery of Encapsulated Cyclosporin A: I. An *in vitro*

Study Using Hairless Mouse Skin", S.T.P. Pharma Sciences, Vol. 3, pp. 404 - 407 (1993), Wallach and Philippot; "New Type of Lipid Vesicle: Novasome®", Liposome Technology, Vol. 1, pp. 141 - 156 (1993), and Wallach, U.S. Patent No. 4,911,928, assigned to Micro-Pak, Inc., issued March 27, 1990.

- 5 The compounds of the present invention may also be administered by iontophoresis. See, e.g., www.unipr.it/arpa/dipfarm/erasmus/erasml4.html, Banga et al., "Hydrogel-based Iontotherapeutic Delivery Devices for Transdermal Delivery of Peptide/Protein Drugs", Pharm. Res., Vol. 10 (5), pp. 697-702 (1993), Ferry L.L., "Theoretical Model of Iontophoresis Utilized in Transdermal Drug Delivery", Pharmaceutical Acta Helvetiae, Vol 70, pp. 279-287 (1995),
- 10 Gangarosa et al., "Modern Iontophoresis for Local Drug Delivery", Int. J. Pharm., Vol. 123, pp. 159-171 (1995), Green et al., "Iontophoretic Delivery of a Series of Tripeptides Across the Skin *in vitro*", Pharm. Res., Vol 8, pp. 1121-1127 (1991), Jadoul et al., "Quantification and Localization of Fentanyl and TRH Delivered by Iontophoresis in the Skin", Int. J. Pharm., Vol. 120, pp. 221-8 (1995), O'Brien et al., "An Updated Review of its Antiviral Activity,
- 15 Pharmacokinetic Properties and Therapeutic Efficacy", Drugs, Vol. 37, pp. 233-309 (1989), Parry et al., "Acyclovir Bioavailability in Human Skin", J. Invest. Dermatol., Vol. 98 (6), pp. 856-63 (1992), Santi et al., "Drug Reservoir Composition and Transport of Salmon Calcitonin in Transdermal Iontophoresis", Pharm. Res., Vol 14 (1), pp. 63-66 (1997), Santi et al., "Reverse Iontophoresis - Parameters Determining Electroosmotic Flow: I. pH and Ionic Strength", J.
- 20 Control. Release, Vol. 38, pp. 159-165 (1996), Santi et al., "Reverse Iontophoresis - Parameters Determining Electroosmotic Flow: II. Electrode Chamber Formulation", J. Control. Release, Vol. 42, pp. 29-36 (1996), Rao et al., "Reverse Iontophoresis: Noninvasive Glucose Monitoring *in vivo* in Humans", Pharm. Res., Vol. 12 (12), pp. 1869-1873 (1995), Thysman et al., "Human Calcitonin Delivery in Rats by Iontophoresis", J. Pharm. Pharmacol., Vol. 46, pp. 725-730
- 25 (1994), Volpato et al., "Iontophoresis Enhances the Transport of Acyclovir through Nude Mouse Skin by Electropulsion and Electroosmosis", Pharm. Res., Vol. 12 (11), pp. 1623-1627 (1995).

The compositions of the present invention may also optionally comprise an activity enhancer. The activity enhancer can be chosen from a wide variety of molecules which can function in different ways to enhance hair growth effects of a compound of the present invention.

- 30 Particular classes of activity enhancers include other hair growth stimulants and penetration enhancers.

Additional hair growth stimulants can be chosen from a wide variety of molecules which can function in different ways to enhance the hair growth effects of a compound of the present invention. These optional other hair growth stimulants, when present, are typically employed in

the compositions herein at a level ranging from about 0.01% to about 15%, preferably from about 0.1% to about 10%, most preferably from about 0.5% to about 5% by weight of the composition.

Vasodilators such as potassium channel agonists including, for example, minoxidil and minoxidil derivatives such as aminexil and such as those described in U.S. Patent 3,382,247, U.S. Patent 5,756,092, issued May 26, 1998, U.S. Patent 5,772,990, issued June 30, 1998, U.S. Patent 5,760,043, issued June 2, 1998, U.S. Patent 3,289,14, issued July 12, 1994, U.S. Patent 5,466,694, issued November 14, 1995, 5,438,058, issued August 1, 1995, and U.S. Patent 4,973,474, issued November 27, 1990, (all of which are herein incorporated by reference), and cromakalin and diazoxide can be used as an additional hair growth stimulant in the compositions herein.

One suitable class of additional hair growth stimulant for use herein are antiandrogens. Examples of suitable antiandrogens may include, but are not limited 5- α -reductase inhibitors such as finasteride and those described in U.S. Patent 5,516,779, issued May 14, 1996 (herein incorporated by reference) and in Nane et al., Cancer Research 58, "Effects of Some Novel Inhibitors of C17,20-Lyase and 5 α -Reductase *in vitro* and *in vivo* and Their Potential Role in the Treatment of Prostate Cancer," as well as cyproterone acetate, azelaic acid and its derivatives and those compounds described in U.S. Patent 5,480,913, issued January 2, 1996, flutamide, and those described in U.S. Patents 5,411,981, issued May 2, 1995, U.S. Patent 5,565,467, issued October 15, 1996 and U.S. Patent 4,910,226, issued March 20, 1990, all of which are herein incorporated by reference.

Another suitable class of optional hair growth stimulants are immunosuppressants or non-immunosuppressants such as 1) cyclosporin and cyclosporin analogs including those described in U.S. Provisional Patent Application No. 60/122,925, Fulmer et al., filed March 5, 1999, herein incorporated by reference, and 2) FK506 analogs such as those described in U.S. Provisional Patent Application No. 60/147,279, Degenhardt et al., filed August 5, 1999; U.S. Provisional Patent Application No. 60/147,313, Degenhardt et al., filed August 5, 1999; U.S. Provisional Patent Application No. 60/147,280, Degenhardt et al., filed August 5, 1999; U.S. Provisional Patent Application No. 60/147,278, Degenhardt et al., filed August 5, 1999; and U.S. Provisional Patent Application No. 60/147,276, Eickhoff et al., filed August 5, 1999; all of which are herein incorporated by reference.

Another suitable class of optional hair growth stimulants are antimicrobials such as selenium sulfide, ketoconazole, triclocarbon, triclosan, zinc pyrithione, itraconazole, asiatic acid, hinokitiol, mipirocin and those described in EPA 0,680,745 (herein incorporated by reference), clinacycin hydrochloride, benzoyl peroxide, benzyl peroxide and minocyclin.

Anti-inflammatories can also be incorporated into the compositions herein as an optional hair growth stimulant. Examples of suitable anti-inflammatories may include glucocorticoids such as hydrocortisone, mometasone furoate and prednisolone, nonsteroidal anti-inflammatories including cyclooxygenase or lipoxygenase inhibitors such as those described in U.S. Patent 5,756,092, and benzydamine, salicylic acid, and those compounds described in EPA 0,770,399, published May 2, 1997, WO 94/06434, published March 31, 1994, and FR 2,268,523, published November 21, 1975, all of which are herein incorporated by reference.

Another suitable class of optional hair growth stimulants are thyroid hormones and derivatives and analogs thereof. Examples of suitable thyroid hormones for use herein may include triiodothyronine. Examples of thyroid hormone analogs which may be suitable for use herein include those described in U.S. Provisional Patent Application No. 60/136,996, Zhang et al., filed June 1, 1999, U.S. Provisional Patent Application No. 60/137,024, Zhang et al., filed June 1, 1999, U.S. Provisional Patent Application No. 60/137,022, Zhang et al., filed June 1, 1999, U.S. Provisional Patent Application No. 60/137,023, Zhang et al., filed June 1, 1999, U.S. Provisional Patent Application No. 60/137,052, Youngquist et al., filed June 1, 1999, U.S. Provisional Patent Application No. 60/137,063, Youngquist et al., filed June 1, 1999, and U.S. Provisional Patent Application No. 60/136,958, Youngquist et al., filed June 1, 1999.

Prostaglandin agonists or antagonists can also be used as optional hair growth stimulants in the compositions herein. Examples of suitable prostaglandins agonists or antagonists include latanoprost and those described in WO 98/33497, Johnstone, published August 6, 1998, WO 95/11003, Stjernschantz, published April 27, 1995, JP 97-100091, Ueno and JP 96-134242, Nakamura.

Another class of optional hair growth stimulants for use herein are retinoids. Suitable retinoids may include isotretinoin, acitretin, and tazarotene.

Another class of optional hair growth stimulants for use herein are triterpenes such as, for example, those disclosed in Bradbury et al., U.S. Patent Application Serial No. 09/353,408, "Method for Regulating Hair Growth", filed July 15, 1999 and Bradbury et al., U.S. Patent Application Serial No. 09/353,409, "Compositions Which Contain Triterpenes for Regulating Hair Growth", filed July 15, 1999, each incorporated by reference in their entirety.

Other classes of optional hair growth stimulants for use herein include flavinoids, ascomycin derivatives and analogs, histamine antagonists such as diphenhydramine hydrochloride, other triterpenes such as oleanolic acid and ursolic acid and those described in U.S. Patent 5,529,769, JP 10017431, WO 95/35103, U.S. Patent 5,468,888, JP 09067253, WO 92/09262, JP 62093215, U.S. Patent 5,631,282, U.S. Patent 5,679,705, JP 08193094, saponins

such as those described in EP 0,558,509 to Bonte et al., published September 8, 1993 and WO 97/01346 to Bonte et al, published January 16, 1997 (both of which are herein incorporated by reference in their entirety), proteoglycanase or glycosaminoglycanase inhibitors such as those described in U.S. Patents 5,015,470, issued May 14, 1991, U.S. Patent 5,300,284, issued April 5,
5 1994 and U.S. Patent 5,185,325, issued February 9, 1993 (all of which are herein incorporated in their entirety by reference) estrogen agonists and antagonists, pseudoterins, cytokine and growth factor promoters, analogs or inhibitors such as interleukin1 inhibitors, interleukin-6 inhibitors, interleukin-10 promoters, and tumor necrosis factor inhibitors, vitamins such as vitamin D analogs and parathyroid hormone antagonists, Vitamin B12 analogs and panthenol, interferon
10 agonists and antagonists, hydroxyacids such as those described in U.S. Patent 5,550,158, benzophenones, and hydantoin anticonvulsants such as phenytoin.

Other additional hair growth stimulants are described in detail in, for example, JP 09-157,139 to Tsuji et al., published June 17, 1997; EP 0277455 A1 to Mirabeau, published August 10, 1988; WO 97/05887 to Cabo Soler et al., published February 20, 1997; WO 92/16186 to
15 Bonte et al., published March 13, 1992; JP 62-93215 to Okazaki et al., published April 28, 1987; U.S. Patent 4,987,150 to Kurono et al., issued January 22, 1991; JP 290811 to Ohba et al., published October 15, 1992; JP 05-286,835 to Tanaka et al., published November 2, 1993, FR 2,723,313 to Greff, published August 2, 1994, U. S. Patent 5,015,470 to Gibson, issued May 14, 1991, U.S. Patent 5,559,092, issued September 24, 1996, U.S. Patent 5,536,751, issued July 16,
20 1996, U.S. Patent 5,714,515, issued February 3, 1998, EPA 0,319,991, published June 14, 1989, EPA 0,357,630, published October 6, 1988, EPA 0,573,253, published December 8, 1993, JP 61-260010, published November 18, 1986, U.S. Patent 5,772,990, issued June 30, 1998, U.S. Patent 5,053, 410, issued October 1, 1991, and U.S. Patent 4,761,401, issued August 2, 1988, all of which are herein incorporated by reference.

25 Non-limiting examples of penetration enhancers which may be used in the compositions herein include, for example, 2-methyl propan-2-ol, propan-2-ol, ethyl-2-hydroxypropanoate, hexan-2,5-diol, POE(2) ethyl ether, di(2-hydroxypropyl) ether, pentan-2,4-diol, acetone, POE(2) methyl ether, 2-hydroxypropionic acid, 2-hydroxyoctanoic acid, propan-1-ol, 1,4-dioxane, tetrahydrofuran, butan-1,4-diol, propylene glycol dipelargonate, polyoxypropylene 15 stearyl
30 ether, octyl alcohol, POE ester of oleyl alcohol, oleyl alcohol, lauryl alcohol, dioctyl adipate, dicapryl adipate, di-isopropyl adipate, di-isopropyl sebacate, dibutyl sebacate, diethyl sebacate, dimethyl sebacate, dioctyl sebacate, dibutyl suberate, dioctyl azelate, dibenzyl sebacate, dibutyl phthalate, dibutyl azelate, ethyl myristate, dimethyl azelate, butyl myristate, dibutyl succinate, didecyl phthalate, decyl oleate, ethyl caproate, ethyl salicylate, *iso*-propyl palmitate, ethyl

laurate, 2-ethyl-hexyl pelargonate, *iso*-propyl isostearate, butyl laurate, benzyl benzoate, butyl benzoate, hexyl laurate, ethyl caprate, ethyl caprylate, butyl stearate, benzyl salicylate, 2-hydroxypropanoic acid, 2-hydroxyoctanoic acid, dimethyl sulphoxide, N,N-dimethyl acetamide, N,N-dimethyl formamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, 5-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, phosphine oxides, sugar esters, tetrahydrofurfural alcohol, urea, diethyl-*m*-toluamide, and, 1-dodecylazacycloheptan-2-one..

In all of the foregoing, of course, the compounds of the invention can be administered alone or as mixtures, and the compositions may further include additional drugs or excipients as appropriate for the indication.

Composition Examples

The following composition and method examples do not limit the invention, but provide guidance to the skilled artisan to prepare and use the compounds, compositions, and methods of the invention. In each example, a compound of the present invention other than the one mentioned may be substituted in the example with similar results.

Example A

A tablet for oral administration according to the present invention is made, comprising:

<u>Component</u>	<u>Amount</u>
Compound of Example 3	15 mg
Lactose	120 mg
Maize Starch	70 mg
Talc	4 mg
Magnesium Stearate	1 mg

A human female subject weighing 60 kg (132 lbs), suffering from rheumatoid arthritis, is treated by a method of this invention. Specifically, for two years, a regimen of three tablets per day of the above composition is administered orally to the subject.

Example B

A composition for topical administration according to the present invention is made, comprising:

<u>Component</u>	<u>Amount</u>
Compound of Example 1	5 %
Ethanol	57 %
Propylene Glycol	19 %
Dimethyl Isosorbide	19 %

- 5 A human male subject suffering from male pattern baldness is treated by a method of this invention. Specifically, for 6 weeks, the above composition is daily administered topically to the subject.

Example C

- 10 A composition for topical administration according to the present invention is made according to the method of Dowton et al., "Influence of Liposomal Composition on Topical Delivery of Encapsulated Cyclosporin A: I. An *in vitro* Study Using Hairless Mouse Skin", S.T.P. Pharma Sciences, Vol. 3, pp. 404 - 407 (1993), using the compound of Example 4 in lieu of cyclosporin A and using the Novasome 1 for the non-ionic liposomal formulation.

- 15 A human male subject suffering from male pattern baldness is treated each day with the above composition. Specifically, for 6 weeks, the above composition is administered topically to the subject.

Example D

A shampoo according to the present invention is made, comprising:

<u>Component</u>	<u>Ex. C-1</u>	<u>Ex. C-2</u>	<u>Ex. C-3</u>	<u>Ex. C-4</u>
Ammonium Lauryl Sulfate	11.5 %	11.5 %	9.5 %	7.5 %
Ammonium Laureth Sulfate	4 %	3 %	2 %	2 %
Cocamide MEA	2 %	2 %	2 %	2 %
Ethylene Glycol Distearate	2 %	2 %	2 %	2 %
Cetyl Alcohol	2 %	2 %	2 %	2 %
Stearyl Alcohol	1.2 %	1.2 %	1.2 %	1.2 %
Glycerin	1 %	1 %	1 %	1 %
Polyquaternium 10	0.5 %	0.25 %	-	-
Polyquaternium 24	-	-	0.5 %	0.25 %
Sodium Chloride	0.1 %	0.1 %	0.1 %	0.1 %


20

Sucrose Polyesters of Cottonate Fatty Acid	3 %	3 %	-	-
--	-----	-----	---	---

Sucrose Polyesters of Behenate Fatty Acid	2 %	3 %	-	-
Polydimethyl Siloxane	-	-	3 %	2 %
Cocaminopropyl Betaine	-	1 %	3 %	3 %
Lauryl Dimethyl Amine Oxide	1.5 %	1.5 %	1.5 %	1.5 %
Decyl Polyglucose	-	-	1 %	1 %
DMDM Hydantoin	0.15 %	0.15 %	0.15 %	0.15 %
Compound of Example 2	2 %	-	-	-
Compound of Example 6	-	5 %	-	-
Compound of Example 7	-	-	3 %	-
Compound of Example 5	-	-	-	6 %
Phenoxyethanol	0.5 %	0.5 %	0.5 %	0.5 %
Fragrance	0.5 %	0.5 %	0.5 %	0.5 %
Water	q.s.	q.s.	q.s.	q.s.

What is claimed is:

1. A compound characterized by the structure:



and pharmaceutically acceptable salts, hydrates, and biohydrolyzable amides, esters, and imides thereof, wherein:

- (a) Z is a saturated or unsaturated 4-, 5-, 6-, 7-, 8-, or 9-membered carbocycle or heterocycle wherein the heterocycle contains one or more heteroatoms selected from the group consisting of O, N, S, S(O), S(O₂), and P((O)OK);
- (b) V is -CU-, wherein U is selected from the group consisting of hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl;
- (c) G is selected from the group consisting of nil, O, S, and NR₁₇;
- (d) K is selected from the group consisting of hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl;
- (e) R₁ is selected from the group consisting of alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl;
- (f) W is selected from the group consisting of nil, hydrogen, and lower alkyl;
- (g) A is selected from the group consisting of nil and alkyl;
- (h) X and Y are each, independently, selected from the group consisting of C(O), P(O), N, O, and S, wherein:
 - (i) when X is C(O) then R₃ is nil and Y is selected from the group consisting of N, O, and S;

- (ii) when X is P(O) then R₃ is nil and Y is selected from the group consisting of N and O;
 - (iii) when X is N then R₃ is selected from hydrogen, alkyl, and arylalkyl, Y is selected from the group consisting of C(O) and P(O), and R₂ is nil;
 - (iv) when X is O then R₃ is nil, Y is selected from the group consisting of C(O) and P(O), and R₂ is nil; and
 - (v) when X is S then R₃ is nil, Y is C(O), and R₂ is nil;
- (f) R₂ and R₃ are each, independently, selected from the group consisting of nil, hydrogen, alkyl, and arylalkyl;
- (g) R₄ is alkyl;
- (h) R₅ and R₆ are each, independently, selected from the group consisting of nil, hydrogen, alkyl having at least two carbon atoms, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl; or wherein R₅ and R₆ are bonded together to form a carbocyclic or heterocyclic ring; wherein at least one of R₅ and R₆ is not nil or hydrogen;
- (i) R₇, R₈, R₉, and R₁₀ are each, independently, selected from the group consisting of nil, hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, halo, cyano, hydroxy, oxo, imino, -R₁₄SR₁₅, -R₁₄S(O₂)R₁₅, -R₁₄S(O)R₁₅, -R₁₄C(O)R₁₅, -R₁₄C(O)NR₁₅R₁₆, -R₁₄C(O)OR₁₅, -R₁₄OR₁₅, -R₁₄NR₁₅R₁₆, -R₁₄P(O)NR₁₅R₁₆, -R₁₄P(O)OR₁₅R₁₆, and a spiro moiety, and wherein R₇ and R₈ may be optionally bonded together to form an aromatic or saturated, carbocyclic or heterocyclic ring wherein the ring is fused to Z;
- (j) R₁₄, and R₁₅ are each, independently, selected from the group consisting of nil, hydrogen, alkyl, alkenyl, heteroalkyl, heteroalkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroarylalkyl, arylalkenyl, and heteroarylalkenyl; and
- (k) R₁₆ and R₁₇ are each, independently, selected from the group consisting of hydrogen and alkyl.
2. A compound according to Claim 1 wherein Z is a 5-, 6-, or 7-membered carbocycle or heterocycle.
3. A compound according to any of the preceding claims wherein Z is a 5-membered carbocycle or heterocycle.

4. A compound according to any of Claims 1 or 2 wherein Z is a 6-membered carbocycle or heterocycle.
5. A compound according to any of the preceding claims wherein G is -NH-, A is nil, X is C(O), Y is N, and R₂ is hydrogen.
6. A compound according to any of the preceding claims wherein R₈, R₉, and R₁₀ are each, independently selected from the group consisting of nil and hydrogen.
7. A compound according to any of Claims 1, 2, 3, 4, or 5 wherein R₇ and R₈ are bonded together to form a 5-, 6-, or 7-membered carbocyclic or heterocyclic aromatic ring which is fused to Z.
8. A composition characterized by a compound according to any of the preceding claims and a pharmaceutically-acceptable carrier.
9. A method of treating hair loss comprising administering to a mammal a composition according to any of the preceding claims.
10. A method of treating or preventing multi-drug resistance comprising administering to a mammal a composition according to any of the preceding claims.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/22213

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C237/22 C07C237/24 C07D307/46 A61K7/06 A61K31/165

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 15101 A (VERTEX PHARMA) 23 May 1996 (1996-05-23) cited in the application abstract; claim 1 ---	1
A	WO 93 04679 A (ABBOTT LAB) 18 March 1993 (1993-03-18) cited in the application abstract; claim 1 ---	1
A,P	EP 0 940 390 A (SHISEIDO CO LTD) 8 September 1999 (1999-09-08) abstract; claims 1,14-19 ---	1,8
A	WO 97 36869 A (VERTEX PHARMA) 9 October 1997 (1997-10-09) abstract -----	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 December 1999

Date of mailing of the international search report

12/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Rufet, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 22213

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 10
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: 1-9
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-9

Present claims 1-9 relate to an extremely large number of possible compounds/compositions/methods. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/products/apparatus/methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds according to formula (I) of claim 1 wherein Z (including V) represents a cyclopentyl or cyclohexyl group, which can be substituted, A is nil (bond), W is hydrogen, -X-Z- is -C(O)N- or -N-C(O)-, R6-R4-R5 represent a substituted or unsubstituted alkyl or arylalkyl group, G is NR17 and R1 represents a substituted or unsubstituted phenyl, alkyl or a furyl group. It is stressed that this definition comprises all the examples of the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/22213

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9615101 A	23-05-1996	US 5543423 A	06-08-1996
		AU 689991 B	09-04-1998
		AU 4109996 A	06-06-1996
		BR 9509698 A	30-06-1998
		CA 2224198 A	23-05-1996
		CZ 9701491 A	15-10-1997
		EP 0797567 A	01-10-1997
		FI 972086 A	15-05-1997
		HU 77977 A	28-01-1999
		JP 10509151 T	08-09-1998
		NO 972217 A	17-06-1997
		NZ 296474 A	28-01-1999
		PL 320227 A	15-09-1997
		SK 61197 A	05-11-1996
		ZA 9509304 A	29-05-1996
WO 9304679 A	18-03-1993	AU 2580492 A	05-04-1993
		AU 669337 B	06-06-1996
		AU 2667392 A	05-04-1993
		AU 686520 B	05-02-1998
		AU 6448396 A	05-12-1996
		CA 2103453 A	06-03-1993
		CA 2103454 A	06-03-1993
		EP 0638082 A	15-02-1995
		EP 0642516 A	15-03-1995
		JP 6510304 T	17-11-1994
		JP 6509583 T	27-10-1994
		WO 9304680 A	18-03-1993
		US 5457111 A	10-10-1995
		US 5561228 A	01-10-1996
		US 5534632 A	09-07-1996
		US 5561137 A	01-10-1996
		US 5604294 A	18-02-1997
		US 5563172 A	08-10-1996
		US 5541193 A	30-07-1996
		US 5604234 A	18-02-1997
		US 5731320 A	24-03-1998
		US 5643918 A	01-07-1997
		US 5708002 A	13-01-1998
EP 0940390 A	08-09-1999	AU 1854499 A	16-09-1999
WO 9736869 A	09-10-1997	US 5717092 A	10-02-1998
		AU 2346597 A	22-10-1997
		CA 2249369 A	09-10-1997
		EP 0891331 A	20-01-1999
		US 5935954 A	10-08-1999